Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 204,452,096
  • Shares Outstanding, K 2,696,190
  • Annual Sales, $ 40,122 M
  • Annual Income, $ 2,394 M
  • 36-Month Beta 0.67
  • Price/Sales 4.91
  • Price/Cash Flow 13.23
  • Price/Book 6.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 1.03
  • Number of Estimates 4
  • High Estimate 1.04
  • Low Estimate 1.00
  • Prior Year 0.98
  • Growth Rate Est. (year over year) +5.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
70.89 +6.97%
on 12/24/18
76.70 -1.13%
on 12/31/18
+2.93 (+4.02%)
since 12/21/18
3-Month
66.10 +14.72%
on 10/25/18
80.19 -5.44%
on 12/04/18
+3.26 (+4.49%)
since 10/22/18
52-Week
52.83 +43.54%
on 04/03/18
80.19 -5.44%
on 12/04/18
+14.58 (+23.80%)
since 01/22/18

Most Recent Stories

More News
J&J's (JNJ) Q4 Earnings Beat, 2019 Sales Forecast Soft

J&J (JNJ) beats estimates for both earnings and sales in the fourth quarter of 2018, leading to an increase in shares in pre-market trading. 2019 sales guidance falls short of expectations.

MRK : 75.83 (-0.05%)
JNJ : 128.80 (-1.45%)
LLY : 117.09 (+0.43%)
ABBV : 88.66 (-0.94%)
Dakshidin Corporation (DKSC), Appoints Senior Management New CFO

Dakshidin Corporation (DKSC) is pleased to announce that Whitechapel Holdings Inc.'s (WCH), current CFO Charles (Chuck) Nuzum has assumed the role of Chief Financial Officer (CFO) of Dakshidin Corporation...

DKSC : 0.0029 (-17.14%)
MRK : 75.83 (-0.05%)
Alnylam & Medison Partner to Market RNAi Products in Israel

Alnylam (ALNY) partners with Israel's Medison Pharma to commercialize Onpattro and other RNAi pipeline candidates under development in the former's portfolio.

MRK : 75.83 (-0.05%)
ALNY : 80.66 (-2.96%)
NVS : 88.32 (-0.75%)
SNY : 41.49 (+0.02%)
Merck to Hold Fourth-Quarter and Full-Year 2018 Sales and Earnings Conference Call on February 1

Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its fourth-quarter and full-year 2018 sales and earnings conference call with institutional investors and analysts...

MRK : 75.83 (-0.05%)
The Zacks Analyst Blog Highlights: Bank of America, Merck, Netflix, IBM and The Bank of New York Mellon

The Zacks Analyst Blog Highlights: Bank of America, Merck, Netflix, IBM and The Bank of New York Mellon

NFLX : 325.16 (-4.11%)
BAC : 29.09 (-0.72%)
IBM : 122.52 (-1.05%)
MRK : 75.83 (-0.05%)
BK : 52.59 (-0.13%)
Global Retinal Pharmaceuticals Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024

Retinal Pharmaceuticals is primarily used to treat retinal-related diseases.Retina is a layer of nerve tissue lining the back of the eye. Retina receives light and convert it into neural signals, and send...

VRX.TO : 30.80 (-3.33%)
SNPHF : 14.8000 (-2.31%)
MRK : 75.83 (-0.05%)
NVS : 88.32 (-0.75%)
REGN : 404.75 (-3.36%)
Merck's Partner Gets FDA Nod for Herceptin Biosimilar

Merck's (MRK) partner, Samsung Bioepis Co. gets FDA approval for Ontruzant, a Herceptin Biosimilar.

MRK : 75.83 (-0.05%)
TEVA : 18.75 (-0.37%)
RHHBY : 32.2050 (-1.24%)
SNY : 41.49 (+0.02%)
Top Analyst Reports for Bank of America, Merck & Netflix

Top Analyst Reports for Bank of America, Merck & Netflix

NFLX : 325.16 (-4.11%)
BAC : 29.09 (-0.72%)
IBM : 122.52 (-1.05%)
MRK : 75.83 (-0.05%)
BK : 52.59 (-0.13%)
AMGN : 201.98 (-0.93%)
Global Women's Health Drugs Market Report 2019-2024 Featuring AbbVie Allergan Bayer, GlaxoSmithKline, Merck & Co., Pfizer & Therapeutics MD

The "Global Women's Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth" report has been added to ResearchAndMarkets.com's...

MRK : 75.83 (-0.05%)
Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies

Aerie's (AERI) Investigational New Drug Application for AR-1105 for the treatment of macular edema due to retinal vein occlusion is accepted by the FDA. The candidate will now enter clinical studies.

BAYRY : 18.7600 (-1.47%)
AERI : 43.99 (unch)
MRK : 75.83 (-0.05%)
REGN : 404.75 (-3.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade MRK with:

Business Summary

Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies...

See More

Key Turning Points

2nd Resistance Point 76.64
1st Resistance Point 76.24
Last Price 75.83
1st Support Level 75.39
2nd Support Level 74.95

See More

52-Week High 80.19
Last Price 75.83
Fibonacci 61.8% 69.74
Fibonacci 50% 66.51
Fibonacci 38.2% 63.28
52-Week Low 52.83

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar